SCHEMBL40122

SCHEMBL40122

O=CNCCOCCOCCOCCC(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.34
ADH1B P00325 3/20 0.33
ADH1A P07327 3/20 0.33
ADH7 P40394 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
HSD17B10 Q99714 1/20 0.32
PRMT1 Q99873 1/20 0.32
TLR2 O60603 1/20 0.32
ADH1C P00326 2/20 0.31
LMNA P02545 1/20 0.31
ALKBH5 Q6P6C2 1/20 0.31
SUCNR1 Q9BXA5 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
ADRA1A P35348 1/20 0.31
EPHX1 P07099 1/20 0.30
ADH4 P08319 1/20 0.30
CD274 Q9NZQ7 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24798449 1.00 SMN1; SMN2 (0.34) SMN1; SMN2ADH1BADH1AADH7MEN1
SCHEMBL26902111 1.00 SMN1; SMN2 (0.34) SMN1; SMN2ADH1BADH1AADH7MEN1
SCHEMBL31228430 1.00 SMN1; SMN2 (0.34) SMN1; SMN2ADH1BADH1AADH7MEN1
SCHEMBL25696346 1.00 SMN1; SMN2 (0.34) SMN1; SMN2ADH1BADH1AADH7MEN1
SCHEMBL27446945 1.00 SMN1; SMN2 (0.34) SMN1; SMN2ADH1BADH1AADH7MEN1
SCHEMBL31697503 0.89 TSHR (0.43) SMN1; SMN2ADH1BADH1AADH7PMP22
SCHEMBL30822384 0.84 EPHX2 (0.40) SMN1; SMN2ADH1BADH1AADH7MEN1
SCHEMBL29465552 0.84 CA12 (0.40) SMN1; SMN2MEN1KMT2AEGLN1
SCHEMBL17229458 0.83 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2ABLMPMP22
SCHEMBL30433408 0.83 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2ABLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596550-A1 COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-06 EP claimed
WO-2024114528-A9 COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF 四川科伦博泰生物医药股份有限公司 2024-10-03 WO claimed
WO-2024114528-A1 COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 WO claimed
EP-4596550-A1 COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-06 EP disclosed
WO-2024233280-A1 HETEROBIFUNCTIONAL SMALL MOLECULES THAT DEUBIQUITINYLATE AND STABILIZE TARGET PROTEINS BY RECRUITING USP7 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-11-14 WO disclosed
WO-2024220874-A2 OTUB1 SMALL-MOLECULE BINDERS AND OTUB1-RECRUITING DEUBIQUITINASE-TARGETING CHIMERAS (DUBTACS) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-10-24 WO disclosed
WO-2024114528-A9 COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF 四川科伦博泰生物医药股份有限公司 2024-10-03 WO disclosed
WO-2024114528-A1 COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 WO disclosed
EP-3584576-B1 BIS-BIOTIN AND BIS-IMINOBIOTIN DERIVATIVES AS LABELS FOR IDENTIFICATION OF POTENTIAL DRUG TARGET PROTEINS FOR DEVELOPMENT OF ANTIBODY DRUGS MITSUI CHEMICALS INC (JP) 2024-05-22 EP disclosed
US-11442066-B2 Method for identifying drug-discovery target protein for development of antibody drug, and method for producing antibody against target protein MITSUI CHEMICALS, INC (JP) 2022-09-13 US disclosed
EP-2591354-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2013-05-15 EP disclosed
EP-2590655-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2013-05-15 EP disclosed
WO-2012006473-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 WO disclosed
WO-2012006475-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11442066-B2 Method for identifying drug-discovery target protein for development of antibody drug, and method for producing antibody against target protein BTD, HLCS, STAMBP SMN1; SMN2 4599/4885ADH1B 2080/4885ADH1A 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.